Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

摘要

Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma. This analysis used pooled data from the SIROCCO ( ClinicalTrials.gov identifier NCT01928771 ) and CALIMA ( ClinicalTrials.gov identifier NCT01914757 ) Phase III studies. Patients aged 12–75?years with severe, uncontrolled asthma receiving high-dosage inhaled corticosteroids plus long-acting βsub2/sub-agonists received benralizumab 30?mg subcutaneously every 8?weeks (Q8W, first three doses every 4?weeks (Q4W)), Q4W or placebo. Baseline factors that influenced benralizumab efficacy were evaluated, including oral corticosteroid (OCS) use, nasal polyposis, pre-bronchodilator forced vital capacity (FVC), prior year exacerbations and age at diagnosis. Efficacy outcomes included annual exacerbation rate and change in pre-bronchodilator forced expiratory volume in 1?s at treatment end relative to placebo. Benralizumab Q8W treatment effect was enhanced with each baseline factor for all patients and those with ≥300?eosinophils·μLsup?1/sup relative to the overall population. OCS use, nasal polyposis and FVC ?1/sup. Baseline clinical factors and blood eosinophil counts can help identify patients potentially responsive to benralizumab.